Diagnostics was the largest of Labcorp Holdings Inc.’s 2 reported lines in fiscal 2025, at $10.88B — 78% of $13.97B.
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2014 | FY 2015 | FY 2016 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $9.42B | $10.14B | $10.88B | |||||||||||||
| Labcorp Diagnostics | — | — | — | |||||||||||||
| Routine Testing | — | — | — | |||||||||||||
| Covance Drug Development | — | — | — | |||||||||||||
| Biopharma Laboratory Services | $2.77B | $2.92B | $3.10B | |||||||||||||
| Genomic & Esoteric Testing | — | — | — | |||||||||||||
| Other Segments | — | — | — | |||||||||||||
| Ontario, Canada | — | — | — | |||||||||||||
| Total | $12.19B | $13.07B | $13.97B |
In fiscal 2025, which ended December 31, 2025, the 2 segments Labcorp Holdings Inc. reported in this breakdown added up to $13.97B. That was up 6.9% from $13.07B in fiscal 2024. Diagnostics was the largest segment, at $10.88B or 77.8% of the total, followed by Biopharma Laboratory Services ($3.10B, 22.2%).
Compared with fiscal 2024, Diagnostics grew the fastest, rising 7.2% to $10.88B. Over fiscal 2023 to 2025, revenue across these segments went from $12.19B to $13.97B, a compound annual growth rate of 7.1%. Diagnostics' share of the total rose from 77.2% to 77.8% over the same years.
The table also keeps 6 segments that Labcorp Holdings Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2010 to 2025, as reported in Labcorp Holdings Inc.'s annual filings.
United States was the largest of Labcorp Holdings Inc.’s 5 reported lines in fiscal 2017, at $6.81B — 78% of $8.78B.
| Geography | FY 2017 |
|---|---|
| United States | $6.81B |
| Other Countries | $853.20M |
| Switzerland | $484.40M |
| Canada | $327.80M |
| United Kingdom | $302.00M |
| Total | $8.78B |
In fiscal 2017, which ended December 31, 2017, the 5 regions Labcorp Holdings Inc. reported in this breakdown added up to $8.78B. United States was the largest region, at $6.81B or 77.6% of the total, followed by Other Countries ($853.20M, 9.7%) and Switzerland ($484.40M, 5.5%). Together, the two largest regions made up 87.3% of this total.
This breakdown covers every fiscal year from 2017 to 2017, as reported in Labcorp Holdings Inc.'s annual filings.
Labcorp Holdings Inc. (LH) breaks its revenue down by segment and region. In fiscal 2025, its largest segment was Diagnostics, with $10.88B or 77.8% of the total, followed by Biopharma Laboratory Services at $3.10B (22.2%).
Diagnostics was Labcorp Holdings Inc.'s largest segment in fiscal 2025, with $10.88B in revenue, 77.8% of the $13.97B reported across its 2 segments.
United States was Labcorp Holdings Inc.'s largest region in fiscal 2017, with $6.81B in revenue, 77.6% of the $8.78B reported across its 5 regions.
Of the Labcorp Holdings Inc. segments reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Diagnostics grew the fastest, rising 7.2% from $10.14B to $10.88B.
Every figure is taken from Labcorp Holdings Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2010 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.